Previous close | 155.77 |
Open | 155.99 |
Bid | 157.52 x 800 |
Ask | 157.89 x 800 |
Day's range | 155.44 - 158.22 |
52-week range | 144.95 - 175.97 |
Volume | |
Avg. volume | 7,131,095 |
Market cap | 380.649B |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | 30.38 |
EPS (TTM) | 5.20 |
Earnings date | 16 Apr 2024 |
Forward dividend & yield | 4.76 (3.01%) |
Ex-dividend date | 16 Feb 2024 |
1y target est | 176.06 |
Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S. District Judge Michael Shipp in Trenton, New Jersey, who is overseeing the lawsuits that have been consolidated in his court, said recent changes in the law and new scientific evidence require a fresh review of the evidence that linked J&J products to ovarian cancer. Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016.
NEW YORK (Reuters) -Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S. District Judge Michael Shipp in Trenton, New Jersey, who is overseeing the lawsuits that have been consolidated in his court, said recent changes in the law and new scientific evidence require a fresh review of the evidence that linked J&J products to ovarian cancer. Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016.
Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.